The postmenopausal osteoporosis market is projected to register a CAGR of 3.9% during the forecast period.
The outbreak of Covid-19 has significantly impacted the healthcare industry, including relative negligence of chronic diseases such as osteoporosis. A survey conducted by the National Osteoporosis Foundation and International Osteoporosis Foundation concluded that the major impact includes delays in scanning for diagnosis, interruptions in the supply of drugs and raw material, an increase in telemedicine consultations, and a decrease in parenteral medicine delivery.
The aging population and lifestyle changes are the key factors responsible for the growth of the postmenopausal osteoporosis market. According to WHO statistics, the proportion of the world’s senior population (more than 60 years old) is expected to double from 12% to 22% from 2015 to 2050. This data showed a continuous increase in the geriatric population within the study period, which is the sufferer of postmenopausal osteoporosis (aged between 50 and 60 years). Hence, the market is projected to grow during the forecast period with an increase in demand for therapy.
Additionally, lifestyle changes such as lack of exercise, high consumption of alcohol or smoking, prolonged work duration, and unhealthy eating habits also impact the menopausal period and lead to osteoporosis in many women worldwide. Age, smoking, alcohol, and consumption of medications used to treat various diseases such as gonadotropins, excess consumption of thyroid hormone, and cytotoxic agents are some of the risk factors for causing low bone density and thereby developing osteoporosis after menopause in women. According to data published by the International Menopause Society (IMS), in 2021, more than 200 million women are estimated to suffer from osteoporosis, and 1 in 3 women aged more than 50 is expected to experience osteoporosis fracture.
Many women are diagnosed with postmenopausal osteoporosis after their first fracture (not before the fracture or as soon as the symptoms started) and hence restricted access to diagnosis and treatment of postmenopausal osteoporosis in under-developed countries hamper the market growth in coming years. Additionally, pricing pressure from generic drugs, as many lost their patent in the last few years, is expected to restrain the market growth.
The bisphosphonates class of drug accounted for the market's maximum share, which can be attributed to their ability to prevent the loss of bone density and thereby minimize the fracture risk by 50%. Additionally, bisphosphonates can be tolerated by most patients on a long-term basis. Hence, they are prescribed for most patients who have early-stage osteoporosis.
Alendronate, risedronate, ibandronate, and zoledronic acid are some of the most prescribed bisphosphonates to prevent and treat postmenopausal osteoporosis. A new regimen through the intravenous route is under investigation, and positive results from the trial can further accelerate the market of bisphosphonates during the forecast period. Bisphosphonates are generally prescribed for five years, and the bone-protective benefit of the drug continues even after the treatment discontinuation. Hence, adherence is also high for the bisphosphonate class of drug.
North America contributes the highest revenue in the market due to its developed healthcare infrastructure, presence of major industry players, high diagnosis and treatment rate, more patient compliance, and large patient base. The United States contributes the maximum share in North America. According to the data published by the Centers for Disease Control and Prevention (CDC) in 2021, about 18.8% of women aged 50 years or more had osteoporosis. The prevalence is expected to increase further due to sedentary lifestyles and unhealthy eating & drinking habits. According to the National Osteoporosis Foundation, it is projected that by 2030, about 71 million Americans will have osteoporosis and low bone mass condition.
High research and development activities due to investment by market players and research institutes are expected to further accelerate the market growth during the forecast period from 2022 to 2027. According to data published on clinicaltrial.gov, about 25 active Phase III and Phase IV clinical trials are going on in the United States. In April 2019, the United States Food and Drug Administration (US FDA) approved a new treatment, Evenity (romosozumab-aqqg), for the treatment of postmenopausal osteoporosis in women at high risk of bone fracture.
The postmenopausal osteoporosis market is fragmented and highly competitive due to several generics in the market. However, some of the key players operating in the market are Novartis International AG, Eli Lilly and CO., Pfizer Inc., Merck & Co., Inc., BiologicsMD, Allergan plc., and Cipla Inc.
Increasing awareness about postmenopausal osteoporosis, developing new drugs, and partnerships or collaborations to reach their drugs at maximum patients are some strategies market players are utilizing to gain market share in the industry.
This product will be delivered within 2 business days.
The outbreak of Covid-19 has significantly impacted the healthcare industry, including relative negligence of chronic diseases such as osteoporosis. A survey conducted by the National Osteoporosis Foundation and International Osteoporosis Foundation concluded that the major impact includes delays in scanning for diagnosis, interruptions in the supply of drugs and raw material, an increase in telemedicine consultations, and a decrease in parenteral medicine delivery.
The aging population and lifestyle changes are the key factors responsible for the growth of the postmenopausal osteoporosis market. According to WHO statistics, the proportion of the world’s senior population (more than 60 years old) is expected to double from 12% to 22% from 2015 to 2050. This data showed a continuous increase in the geriatric population within the study period, which is the sufferer of postmenopausal osteoporosis (aged between 50 and 60 years). Hence, the market is projected to grow during the forecast period with an increase in demand for therapy.
Additionally, lifestyle changes such as lack of exercise, high consumption of alcohol or smoking, prolonged work duration, and unhealthy eating habits also impact the menopausal period and lead to osteoporosis in many women worldwide. Age, smoking, alcohol, and consumption of medications used to treat various diseases such as gonadotropins, excess consumption of thyroid hormone, and cytotoxic agents are some of the risk factors for causing low bone density and thereby developing osteoporosis after menopause in women. According to data published by the International Menopause Society (IMS), in 2021, more than 200 million women are estimated to suffer from osteoporosis, and 1 in 3 women aged more than 50 is expected to experience osteoporosis fracture.
Many women are diagnosed with postmenopausal osteoporosis after their first fracture (not before the fracture or as soon as the symptoms started) and hence restricted access to diagnosis and treatment of postmenopausal osteoporosis in under-developed countries hamper the market growth in coming years. Additionally, pricing pressure from generic drugs, as many lost their patent in the last few years, is expected to restrain the market growth.
Key Market Trends
The Bisphosphonates Segment Held the Largest Share of the Market in 2021 and is Projected to Observe the Same Dominance During the Forecast Period
The bisphosphonates class of drug accounted for the market's maximum share, which can be attributed to their ability to prevent the loss of bone density and thereby minimize the fracture risk by 50%. Additionally, bisphosphonates can be tolerated by most patients on a long-term basis. Hence, they are prescribed for most patients who have early-stage osteoporosis.
Alendronate, risedronate, ibandronate, and zoledronic acid are some of the most prescribed bisphosphonates to prevent and treat postmenopausal osteoporosis. A new regimen through the intravenous route is under investigation, and positive results from the trial can further accelerate the market of bisphosphonates during the forecast period. Bisphosphonates are generally prescribed for five years, and the bone-protective benefit of the drug continues even after the treatment discontinuation. Hence, adherence is also high for the bisphosphonate class of drug.
North America Dominates the Global Postmenopausal Osteoporosis Market and is Expected to do the Same in the Forecast Period
North America contributes the highest revenue in the market due to its developed healthcare infrastructure, presence of major industry players, high diagnosis and treatment rate, more patient compliance, and large patient base. The United States contributes the maximum share in North America. According to the data published by the Centers for Disease Control and Prevention (CDC) in 2021, about 18.8% of women aged 50 years or more had osteoporosis. The prevalence is expected to increase further due to sedentary lifestyles and unhealthy eating & drinking habits. According to the National Osteoporosis Foundation, it is projected that by 2030, about 71 million Americans will have osteoporosis and low bone mass condition.
High research and development activities due to investment by market players and research institutes are expected to further accelerate the market growth during the forecast period from 2022 to 2027. According to data published on clinicaltrial.gov, about 25 active Phase III and Phase IV clinical trials are going on in the United States. In April 2019, the United States Food and Drug Administration (US FDA) approved a new treatment, Evenity (romosozumab-aqqg), for the treatment of postmenopausal osteoporosis in women at high risk of bone fracture.
Competitive Landscape
The postmenopausal osteoporosis market is fragmented and highly competitive due to several generics in the market. However, some of the key players operating in the market are Novartis International AG, Eli Lilly and CO., Pfizer Inc., Merck & Co., Inc., BiologicsMD, Allergan plc., and Cipla Inc.
Increasing awareness about postmenopausal osteoporosis, developing new drugs, and partnerships or collaborations to reach their drugs at maximum patients are some strategies market players are utilizing to gain market share in the industry.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- Eli Lilly and CO.
- Pfizer Inc.
- Proctor & Gamble Co.
- Novartis International AG
- Clonz Biotech
- Ligand Pharmaceuticals Incorporated.
- Merck & Co., Inc
- BiologicsMD
- Enteris BioPharma
- Oncobiologics, Inc.
- Allergan plc
Methodology
LOADING...
